The WebEx link for theupcoming lecture is available here.
Lecture abstract
Traditional methods of delivering drugs to the eye include eyedrops and injections directly into the back of the eye. However, these methods are typically ineffective, requiring high doses and multiple treatments for efficacy and in many cases suffer from compliance issues. Polymeric drug delivery has the potential to overcome some of these limitations, providing more constant doses of the drug of interest over a prolonged period of time, with less need for patient input. The talk will focus on technologies developed through the C20/20 Innovation Hub. A mucoadhesive micelle based formulation has been widely examined for the release of a number of different drugs including cyclosporine A for the treatment of dry eye disease. Models of disease demonstrate that a single drop given twice per week is as efficacious as twice daily drops of Restasis, the current FDA approved formulation. Ongoing work including new formulations with alternative binding mechanisms as well as mucopenetrative systems will be discussed. Binding the mucosa of the eye was shown to occur for periods of up to 10 days. Ongoing work including new formulations with alternative binding mechanisms as well as mucopenetrative systems will be discussed. In the back of the eye, injectable, in situ gelable formulations have been examined for the delivery of various therapeutics, including protein therapeutics. The formulations have been shown to be safe and ongoing work is focused on extending release periods to as much as 6 months. Work on the optimization of these formulations will be described.
Speaker bio
